Clinical Trial Update: Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) [Phase 3]

View source ↗

Summary

Phase 3 extension study assessing extending Letermovir prophylaxis from day 100 to day 200 after hematopoietic stem cell transplantation to prevent CMV infectio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cytomegalovirus Infection | Phase 3 | Status: COMPLETED | Results posted: 2022-11-01